Market Overview

Why Biomarin's Stock Is Trading Higher Today

Share:

BioMarin Pharmaceutical (NASDAQ: BMRN) shares are trading higher on Wednesday, after Bank of Americamaintained its Buy rating on the stock and raised the price target from $120 to $130 per share.

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently.

BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA).

BioMarin shares are trading up 1.73% at $106.91 at time of publication on Wednesday. The stock has a 52-week high of $112.57 and a 52-week low of $62.88.

Related Links:

UK Clears Gilead's Remdesivir For Some Coronavirus Patients

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Latest Ratings for BMRN

DateFirmActionFromTo
Sep 2020Truist SecuritiesMaintainsBuy
Aug 2020Morgan StanleyMaintainsEqual-Weight
Aug 2020Canaccord GenuityMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Analyst Ratings

Latest Ratings

StockFirmActionPT
AMDSusquehannaMaintains95.0
BABAOppenheimerMaintains335.0
EAJefferiesMaintains150.0
MELIJefferiesMaintains1,560.0
NOMDBTIGInitiates Coverage On30.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com